南京地区23家医院2006～2008年调脂药利用分析  

Utilization of Lipid-modulating Drugs in 23 Hospitals of Nanjing from 2006 to 2008

作　　者：王亚娜[1] 沈健[1] 陈友亮[1] 王淑云[1] 邱召娟[1] 丁琛[1] 

机构地区：[1]江苏省中医院药剂科,南京市210029

出　　处：《中国药房》2010年第26期2412-2414,共3页China Pharmacy

摘　　要：目的:评价南京地区23家医院调脂药的应用情况及趋势。方法:对南京市23家医院2006～2008年调脂药的应用品种、销售金额及用药频度进行统计、分析。结果:3年中南京地区医院调脂药销售金额和用药频度逐年增加,主要品种有辛伐他汀、阿托伐他汀、血脂康。结论:他汀类药物在调脂药市场中占主导地位,以阿托伐他汀为代表的"超级他汀"增长迅速,以血脂康为代表的中成药制剂销售前景看好。OBJECTIVE：To evaluate the utilization and tendency of lipid-modulating drugs in 23 hospitals of Nanjing. METHODS： The utilization of lipid-modulating drugs in 23 hospitals of Nanjing from 2006 to 2008 was analyzed statistically in terms of drug category, consumption sum and DDDs, etc. RESULTS： The consumption sum and DDDs of lipid-modulating drugs in Nanjing, predominantly simvastatin, atorvastatin, Xuezhikang, increased year by year. CONCLUSION： Statins is the dominant kind of lipid-modulating drugs. The utilization of ＂super-statins＂, e.g. atorvastatin, increased rapidly. The prospects for sales of Chinese patent medicine, such as Xuezhikang, will be quite good.

关 键 词：调脂药 销售金额 用药频度 

分 类 号：R969.3[医药卫生—药理学] R287[医药卫生—药学]